| Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders O Devinsky, MR Cilio, H Cross, J Fernandez‐Ruiz, J French, C Hill, ... Epilepsia 55 (6), 791-802, 2014 | 1107 | 2014 |
| Pharmacological and biochemical interactions between opioids and cannabinoids J Manzanares, J Corchero, J Romero, JJ Fernández-Ruiz, JA Ramos, ... Trends in Pharmacological Sciences 20 (7), 287-294, 1999 | 483 | 1999 |
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease I Lastres-Becker, F Molina-Holgado, JA Ramos, R Mechoulam, ... Neurobiology of disease 19 (1-2), 96-107, 2005 | 470 | 2005 |
| Cannabinoid CB2 receptor: a new target for controlling neural cell survival? J Fernández-Ruiz, J Romero, G Velasco, RM Tolón, JA Ramos, ... Trends in pharmacological sciences 28 (1), 39-45, 2007 | 448 | 2007 |
| Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration S Gispert, F Ricciardi, A Kurz, M Azizov, HH Hoepken, D Becker, W Voos, ... PloS one 4 (6), e5777, 2009 | 440 | 2009 |
| The endogenous cannabinoid system and brain development J Fernández-Ruiz, F Berrendero, ML Hernández, JA Ramos Trends in neurosciences 23 (1), 14-20, 2000 | 432 | 2000 |
| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity J Palazuelos, T Aguado, MR Pazos, B Julien, C Carrasco, E Resel, ... Brain 132 (11), 3152-3164, 2009 | 422 | 2009 |
| Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? J Fernández‐Ruiz, O Sagredo, MR Pazos, C García, R Pertwee, ... British journal of clinical pharmacology 75 (2), 323-333, 2013 | 412 | 2013 |
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties M García-Arencibia, S González, E de Lago, JA Ramos, R Mechoulam, ... Brain research 1134, 162-170, 2007 | 353 | 2007 |
| Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism A Jazwa, AI Rojo, NG Innamorato, M Hesse, J Fernández-Ruiz, ... Antioxidants & redox signaling 14 (12), 2347-2360, 2011 | 323 | 2011 |
| Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine S González, MG Cascio, J Fernández-Ruiz, F Fezza, V Di Marzo, ... Brain research 954 (1), 73-81, 2002 | 318 | 2002 |
| The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors A Castillo, MR Tolón, J Fernández-Ruiz, J Romero, J Martinez-Orgado Neurobiology of disease 37 (2), 434-440, 2010 | 314 | 2010 |
| Cannabinoid tolerance and dependence: a review of studies in laboratory animals S González, M Cebeira, J Fernández-Ruiz Pharmacology Biochemistry and Behavior 81 (2), 300-318, 2005 | 270 | 2005 |
| Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease C García, C Palomo‐Garo, M García‐Arencibia, JA Ramos, RG Pertwee, ... British journal of pharmacology 163 (7), 1495-1506, 2011 | 245 | 2011 |
| Downregulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment FR De Fonseca, MA Gorriti, JJ Fernandez-Ruiz, T Palomo, JA Ramos Pharmacology Biochemistry and Behavior 47 (1), 33-40, 1994 | 233 | 1994 |
| Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease C Blázquez, A Chiarlone, O Sagredo, T Aguado, MR Pazos, E Resel, ... Brain 134 (1), 119-136, 2011 | 232 | 2011 |
| The endocannabinoid system as a target for the treatment of motor dysfunction J Fernández‐Ruiz British journal of pharmacology 156 (7), 1029-1040, 2009 | 228 | 2009 |
| Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP … I Lastres‐Becker, M Cebeira, ML De Ceballos, BY Zeng, P Jenner, ... European Journal of Neuroscience 14 (11), 1827-1832, 2001 | 218 | 2001 |
| Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland S González, T Bisogno, T Wenger, J Manzanares, A Milone, F Berrendero, ... Biochemical and biophysical research communications 270 (1), 260-266, 2000 | 214 | 2000 |
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease O Sagredo, S González, I Aroyo, MR Pazos, C Benito, I Lastres‐Becker, ... Glia 57 (11), 1154-1167, 2009 | 211 | 2009 |
